Sandra Y. Lin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Sandra Y. Lin has a total of 231 co-authors. Here are the top co-authors by number of shared publications:
Christopher R. Roxbury
Department of Otolaryngology—Head and Neck Surgery The University of Chicago Medical Center Chicago Illinois U.S.A.
6 shared publicationsJonathan Liang
Department of Otolaryngology-Head and Neck Surgery, Johns Hopkins School of Medicine, Baltimore, Maryland, U.S.A.
4 shared publicationsMurugappan Ramanathan
Department of Otolaryngology-Head and Neck Surgery, Johns Hopkins University School of Medicine, Baltimore, MD
4 shared publications- Stacey L. Ishman
Cincinnati Children’s Hospital Medical Center
4 shared publications Yohalakshmi Chelladurai
The Johns Hopkins Evidence-Based Practice Center bDepartment of Otolaryngology-Head and Neck Surgery, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
4 shared publications- Antonella Muraro
Food Allergy Referral Centre, Veneto Region, Department of Women’s and Children’s Health, Padua University Hospital, 35128 Padua, Italy
3 shared publications
Latest Publications
- 24 September 2021
- Published by Elsevier in Clinical Radiology
- Vol. 76 (12) , 930-934
Model-based iterative reconstruction in CT of paranasal sinuses in cystic fibrosis
- 24 September 2021
- Published by Elsevier in Clinical Radiology
- Vol. 76 (12) , 930-934
Model-based iterative reconstruction in CT of paranasal sinuses in cystic fibrosis
- 12 August 2021
- Published by Wiley in The Laryngoscope
- Vol. 132 (1) , 177-187
Magnetic Resonance Imaging Findings Among Individuals With Olfactory and Cognitive Impairment
Objectives: The underlying mechanism of the association between olfactory impairment and dementia may be explained by neurodegenerative changes detected on magnetic resonance imaging (MRI). The purpose of this systematic review is to describe neurodegenerative changes on MRI in patients with olfactory impairment and mild cognitive impairment (MCI) or dementia. Study design: Systematic review. Methods: A literature search encompassing PubMed, Embase, Cochrane Library, Web of Science, Scopus, and Google Scholar for studies with MRI and olfactory testing among participants diagnosed with MCI or dementia was performed. Sample size, study design, cognitive impairment type, olfactory testing, and MRI findings were abstracted. Two investigators independently reviewed all articles. Results: The search yielded 556 nonduplicate abstracts, from which 86 articles were reviewed and 24 were included. Seventeen (71%) of 24 studies reported hippocampal volume findings, with 14 studies reporting a relationship between hippocampal volume and olfactory performance. Two (50%) of four prospective studies reported the potential utility of baseline hippocampal volume as a marker of dementia conversion from MCI. Five (21%) of 24 studies reporting olfactory functional MRI (fMRI) findings highlighted the utility of olfactory fMRI to identify individuals in the early stages of cognitive decline. Conclusion: Current evidence suggests hippocampal volume correlates with olfactory performance in individuals with cognitive impairment, and that olfactory fMRI may improve early detection of AD. However, the predictive utility of these imaging markers is limited in prospective studies. MRI may be a useful modality for selecting patients at high risk of future cognitive decline for enrollment in early treatment trials. Laryngoscope , 132:177–187, 2022
- 12 August 2021
- Published by Wiley in The Laryngoscope
- Vol. 132 (1) , 177-187
Magnetic Resonance Imaging Findings Among Individuals With Olfactory and Cognitive Impairment
Objectives: The underlying mechanism of the association between olfactory impairment and dementia may be explained by neurodegenerative changes detected on magnetic resonance imaging (MRI). The purpose of this systematic review is to describe neurodegenerative changes on MRI in patients with olfactory impairment and mild cognitive impairment (MCI) or dementia. Study design: Systematic review. Methods: A literature search encompassing PubMed, Embase, Cochrane Library, Web of Science, Scopus, and Google Scholar for studies with MRI and olfactory testing among participants diagnosed with MCI or dementia was performed. Sample size, study design, cognitive impairment type, olfactory testing, and MRI findings were abstracted. Two investigators independently reviewed all articles. Results: The search yielded 556 nonduplicate abstracts, from which 86 articles were reviewed and 24 were included. Seventeen (71%) of 24 studies reported hippocampal volume findings, with 14 studies reporting a relationship between hippocampal volume and olfactory performance. Two (50%) of four prospective studies reported the potential utility of baseline hippocampal volume as a marker of dementia conversion from MCI. Five (21%) of 24 studies reporting olfactory functional MRI (fMRI) findings highlighted the utility of olfactory fMRI to identify individuals in the early stages of cognitive decline. Conclusion: Current evidence suggests hippocampal volume correlates with olfactory performance in individuals with cognitive impairment, and that olfactory fMRI may improve early detection of AD. However, the predictive utility of these imaging markers is limited in prospective studies. MRI may be a useful modality for selecting patients at high risk of future cognitive decline for enrollment in early treatment trials. Laryngoscope , 132:177–187, 2022
- Open Access
- 3 June 2021
- Published by Wiley in Anz Journal of Surgery
- Vol. 91 (9) , 1744-1750
Experience with NovoSorb® Biodegradable Temporising Matrix in reconstruction of complex wounds
Background: The NovoSorb® Biodegradable Temporising Matrix (BTM) is a synthetic polyurethane dermal matrix used to reconstruct complex wounds including deep dermal and full‐thickness burns, necrotising fasciitis and free flap donor site. We hope to further explore its potential applications in this series.Methods: Patients who received BTM application across four centres over an 18‐month period were included. Patients were followed up to assess BTM and graft take, the aesthetic, the return of sensation and complications.Results: A total of 27 patients with 35 wounds were identified with a range of aetiologies. Thirty‐three wounds had 100% integration of BTM at the time of sealing membrane removal. Seven wounds had partial graft loss that later healed by secondary intention. In two cases, re‐epithelialisation occurred with BTM alone without split‐skin graft.Conclusion: BTM offers a safe and reliable reconstructive option in challenging wounds that would otherwise require more complex operations.
- 3 June 2021
- Published by Wiley in Anz Journal of Surgery
- Vol. 91 (9) , 1744-1750
Open AccessExperience with NovoSorb® Biodegradable Temporising Matrix in reconstruction of complex wounds
Background: The NovoSorb® Biodegradable Temporising Matrix (BTM) is a synthetic polyurethane dermal matrix used to reconstruct complex wounds including deep dermal and full‐thickness burns, necrotising fasciitis and free flap donor site. We hope to further explore its potential applications in this series.Methods: Patients who received BTM application across four centres over an 18‐month period were included. Patients were followed up to assess BTM and graft take, the aesthetic, the return of sensation and complications.Results: A total of 27 patients with 35 wounds were identified with a range of aetiologies. Thirty‐three wounds had 100% integration of BTM at the time of sealing membrane removal. Seven wounds had partial graft loss that later healed by secondary intention. In two cases, re‐epithelialisation occurred with BTM alone without split‐skin graft.Conclusion: BTM offers a safe and reliable reconstructive option in challenging wounds that would otherwise require more complex operations.
- 19 April 2021
- Published by Springer Nature in Eating and Weight Disorders - Studies on Anorexia, Bulimia and Obesity
- Vol. 27 (2) , 429-447
Psychophysical chemosensory dysfunction in eating disorders: a qualitative systematic review
Purpose Patients with chemosensory dysfunction experience significant quality of life disruptions, including reduced enjoyment of eating. While chemosensory dysfunction has been associated with eating disorders, the relationship is poorly understood. This systematic review aims to characterize psychophysical gustation and olfaction in patients with eating disorders. Methods Systematic review of investigations assessing psychophysical chemosensory function in patients with organic eating disorders. Results 26 studies were included. Five studies assessed both chemosenses, while 12 and 9 assessed exclusively gustation or olfaction, respectively. In total, 779 patients were included [72.4% anorexia nervosa (AN), 26.7% bulimia nervosa (BN), 0.8% combined AN/BN]. Patients with eating disorders experienced rates of hypogeusia up to 87% in AN and 84.6% in BN. There was evidence for alterations in psychophysical olfaction, but orientation of trends were less clear. Chemosensory dysfunction was more evident in AN patients. Treatment correlated with improved chemosensory function. Conclusions Despite heterogeneity in study methodology and results, this review demonstrates that patients with eating disorders experience some degree of chemosensory dysfunction, particularly in gustation. This symptomatology overlaps with those experienced by patients with other causes of chemosensory impairment. These findings suggest potential broad psychosocial, dietary, and mental health implications in patient populations experiencing chemosensory dysfunction. Level of evidence Level II.
- 19 April 2021
- Published by Springer Nature in Eating and Weight Disorders - Studies on Anorexia, Bulimia and Obesity
- Vol. 27 (2) , 429-447
Psychophysical chemosensory dysfunction in eating disorders: a qualitative systematic review
Purpose Patients with chemosensory dysfunction experience significant quality of life disruptions, including reduced enjoyment of eating. While chemosensory dysfunction has been associated with eating disorders, the relationship is poorly understood. This systematic review aims to characterize psychophysical gustation and olfaction in patients with eating disorders. Methods Systematic review of investigations assessing psychophysical chemosensory function in patients with organic eating disorders. Results 26 studies were included. Five studies assessed both chemosenses, while 12 and 9 assessed exclusively gustation or olfaction, respectively. In total, 779 patients were included [72.4% anorexia nervosa (AN), 26.7% bulimia nervosa (BN), 0.8% combined AN/BN]. Patients with eating disorders experienced rates of hypogeusia up to 87% in AN and 84.6% in BN. There was evidence for alterations in psychophysical olfaction, but orientation of trends were less clear. Chemosensory dysfunction was more evident in AN patients. Treatment correlated with improved chemosensory function. Conclusions Despite heterogeneity in study methodology and results, this review demonstrates that patients with eating disorders experience some degree of chemosensory dysfunction, particularly in gustation. This symptomatology overlaps with those experienced by patients with other causes of chemosensory impairment. These findings suggest potential broad psychosocial, dietary, and mental health implications in patient populations experiencing chemosensory dysfunction. Level of evidence Level II.
- 12 January 2021
- Published by Wiley in International Forum of Allergy & Rhinology
- Vol. 11 (1) , 5
Valuing diversity, equity, and inclusion
- 12 January 2021
- Published by Wiley in International Forum of Allergy & Rhinology
- Vol. 11 (1) , 5
Valuing diversity, equity, and inclusion
- 12 November 2020
- Published by Wiley in The Laryngoscope
- Vol. 131 (7) , E2111-E2115
Predictors of Completion of Sublingual Immunotherapy
Objectives: Sublingual immunotherapy (SLIT) has emerged as an effective treatment alternative to subcutaneous immunotherapy (SCIT) given its improved safety profile and more convenient dosing. However, SLIT still relies on daily dosing for many years to optimize effectiveness. This study sought to investigate factors that influence patient completion of SLIT.Methods: We performed an institutional retrospective review of patients who received SLIT (2008–2020). Completion was defined as completing at least 36 months of SLIT. Patient demographics and characteristics, including the number of allergens treated, history of asthma and sinus surgery, number of clinic visits, and total time undergoing SLIT, were documented. Multivariate models were used to analyze predictors of SLIT completion. Subgroup analysis was performed among pediatric patients and patients who discontinued SLIT.Results: Of the 404 total patients, 249 (61.6%) discontinued, 47 (11.6%) completed, and 108 (26.7%) were currently undergoing SLIT. The mean duration of therapy was 11.2 months for those who discontinued and 49.4 months for patients who completed SLIT. The odds of SLIT completion were twice as high with each additional clinic visit (P < .001), and twice as high when the dosage was increased during therapy (P = .06). Pediatric patients younger than age 12 with a history of asthma were over five times more likely to complete therapy (P = .045). Patients with more clinic visits (P < .001) and higher associated costs (P = .003) were less likely to be lost to follow‐up.Conclusion: Increasing the frequency of clinic visits, improving therapy availability, and mitigating concerns about clinical efficacy may increase patient completion of SLIT.Level of Evidence: 4 Laryngoscope, 131:E2111–E2115, 2021
- 12 November 2020
- Published by Wiley in The Laryngoscope
- Vol. 131 (7) , E2111-E2115
Predictors of Completion of Sublingual Immunotherapy
Objectives: Sublingual immunotherapy (SLIT) has emerged as an effective treatment alternative to subcutaneous immunotherapy (SCIT) given its improved safety profile and more convenient dosing. However, SLIT still relies on daily dosing for many years to optimize effectiveness. This study sought to investigate factors that influence patient completion of SLIT.Methods: We performed an institutional retrospective review of patients who received SLIT (2008–2020). Completion was defined as completing at least 36 months of SLIT. Patient demographics and characteristics, including the number of allergens treated, history of asthma and sinus surgery, number of clinic visits, and total time undergoing SLIT, were documented. Multivariate models were used to analyze predictors of SLIT completion. Subgroup analysis was performed among pediatric patients and patients who discontinued SLIT.Results: Of the 404 total patients, 249 (61.6%) discontinued, 47 (11.6%) completed, and 108 (26.7%) were currently undergoing SLIT. The mean duration of therapy was 11.2 months for those who discontinued and 49.4 months for patients who completed SLIT. The odds of SLIT completion were twice as high with each additional clinic visit (P < .001), and twice as high when the dosage was increased during therapy (P = .06). Pediatric patients younger than age 12 with a history of asthma were over five times more likely to complete therapy (P = .045). Patients with more clinic visits (P < .001) and higher associated costs (P = .003) were less likely to be lost to follow‐up.Conclusion: Increasing the frequency of clinic visits, improving therapy availability, and mitigating concerns about clinical efficacy may increase patient completion of SLIT.Level of Evidence: 4 Laryngoscope, 131:E2111–E2115, 2021
- 1 October 2020
- Published by Wiley in International Forum of Allergy & Rhinology
- Vol. 10 (10) , 1125-1126
Sublingual immunotherapy in the United States: history and current relevance in the time of COVID-19
- 1 October 2020
- Published by Wiley in International Forum of Allergy & Rhinology
- Vol. 10 (10) , 1125-1126
Sublingual immunotherapy in the United States: history and current relevance in the time of COVID-19
- 17 February 2020
- Published by Elsevier in Immunology and Allergy Clinics of North America
- Vol. 40 (2) , XVII-XVIII
Chronic Rhinosinusitis: An Evolution of Knowledge
- 17 February 2020
- Published by Elsevier in Immunology and Allergy Clinics of North America
- Vol. 40 (2) , XVII-XVIII
Chronic Rhinosinusitis: An Evolution of Knowledge
- Open Access
- 7 August 2019
- Published by Wiley in Laryngoscope Investigative Otolaryngology
- Vol. 4 (5) , 465-475
The association between diabetes and olfactory impairment in adults: A systematic review and meta‐analysis
Background: Evidence suggests that olfactory impairment (OI) may be a degenerative neurologic complication of diabetes; however, the association is not yet well established. The objective of this work was to systematically review existing literature on the association between diabetes and OI in adults, with meta‐analysis of evaluable studies.Methods: A literature search encompassing 358 abstracts from the last 75 years in PubMed, EMBASE, and Cochrane was performed. English‐language articles investigating adults with diabetes and OI in comparison to control groups with original data and ≥7 subjects were included. The Newcastle‐Ottawa scale was applied for quality assessment. Two investigators independently reviewed all articles. For meta‐analysis, the odds ratio of OI in diabetes compared with control groups was calculated using the fixed effects model.Results: The initial search yielded 358 abstracts, from which 21 articles were reviewed and 11 articles (n = 6,747) were included. Studies included were case‐control (64%) or cross‐sectional (36%) with evidence level 3b. On the Newcastle‐Ottawa scale, the mean quality assessment score for case‐control and cross‐sectional studies was 7.4 (maximum of 9) and 7.0 (maximum of 10), respectively. A statistically significant association between diabetes and olfaction compared with controls was found in 6 (55%) of the 11 articles. Four studies were eligible for meta‐analysis, which yielded an overall odds of having OI with diabetes as 1.58 times more likely than in control groups (95% CI [1.16, 2.16]; I2 = 10.3%).Conclusions: The reviewed studies support a significant association between diabetes and OI. Further studies are warranted to characterize this association.Level of Evidence: 3a
- 7 August 2019
- Published by Wiley in Laryngoscope Investigative Otolaryngology
- Vol. 4 (5) , 465-475
Open AccessThe association between diabetes and olfactory impairment in adults: A systematic review and meta‐analysis
Background: Evidence suggests that olfactory impairment (OI) may be a degenerative neurologic complication of diabetes; however, the association is not yet well established. The objective of this work was to systematically review existing literature on the association between diabetes and OI in adults, with meta‐analysis of evaluable studies.Methods: A literature search encompassing 358 abstracts from the last 75 years in PubMed, EMBASE, and Cochrane was performed. English‐language articles investigating adults with diabetes and OI in comparison to control groups with original data and ≥7 subjects were included. The Newcastle‐Ottawa scale was applied for quality assessment. Two investigators independently reviewed all articles. For meta‐analysis, the odds ratio of OI in diabetes compared with control groups was calculated using the fixed effects model.Results: The initial search yielded 358 abstracts, from which 21 articles were reviewed and 11 articles (n = 6,747) were included. Studies included were case‐control (64%) or cross‐sectional (36%) with evidence level 3b. On the Newcastle‐Ottawa scale, the mean quality assessment score for case‐control and cross‐sectional studies was 7.4 (maximum of 9) and 7.0 (maximum of 10), respectively. A statistically significant association between diabetes and olfaction compared with controls was found in 6 (55%) of the 11 articles. Four studies were eligible for meta‐analysis, which yielded an overall odds of having OI with diabetes as 1.58 times more likely than in control groups (95% CI [1.16, 2.16]; I2 = 10.3%).Conclusions: The reviewed studies support a significant association between diabetes and OI. Further studies are warranted to characterize this association.Level of Evidence: 3a